Beijing Tongrentang Co Ltd (600085) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Beijing Tongrentang Co., Ltd engages in the production and sale of traditional Chinese medicine preparations in China and internationally. The company offers various product dosage forms, such as pills, powders, medicated wines, capsules, oral liquids, and drop pills.
Total Revenue Chart for Beijing Tongrentang Co Ltd
Beijing Tongrentang Co Ltd (600085) revenue for FY2025 was CNY 17.3B, a -7.2% change from FY2024. Beijing Tongrentang Co Ltd's revenue grew from CNY 462.9M in 1994 to CNY 17.3B in 2025 (3628.0% over 31 years). Earnings per share grew from CNY 0.11 in 2000 to CNY 1.04 in 2022 (822.7%). Revenue compound annual growth rate: 5-year CAGR of 6.1%, 10-year CAGR of 4.7%, 20-year CAGR of 9.9%.
Total Revenue (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥33.11B
- Implied Share Price
- ¥24.14
- Enterprise Value
- ¥25.33B
- Revenue (TTM)
- ¥15.87B
- EBITDA
- ¥1.79B
- Profit Margin
- 6.11%
- Trailing P/E
- 34.00
- Forward P/E
- 28.17
- Price/Book (MRQ)
- 2.40
- Price/Sales (TTM)
- 2.09
- EV/EBITDA
- 9.12
- EV/Revenue
- 1.58
- Dividend Yield
- 4.19%
- Book Value
- ¥9.93
- Free Cash Flow (FY2025)
- ¥2.34B
- Free Cash Flow Yield
- 7.05%
Snapshot as of 5th September 2026 — not point-in-time controlled, may lag the live market by a few days.